Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of LTBI Treatment on Glucose Tolerance
NCT04830462Phase 4Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifampicin, isoniazid in Tuberculosis (TB), sponsored by Herlev & Gentofte Hospital. Started Apr 2021; status: completed.
02
Drugs
rifampicinisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04830462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830462.